Cascadian Therapeutics Inc. (CASC) Given Buy Rating at Cowen and Company
Cascadian Therapeutics Inc. (NASDAQ:CASC)‘s stock had its “buy” rating restated by analysts at Cowen and Company in a research note issued on Monday.
CASC has been the subject of several other reports. Zacks Investment Research upgraded Cascadian Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a research report on Tuesday, June 14th. Cantor Fitzgerald restated a “hold” rating and set a $2.00 target price on shares of Cascadian Therapeutics in a research report on Wednesday, June 15th. Finally, Jefferies Group restated a “buy” rating on shares of Cascadian Therapeutics in a research report on Wednesday, June 15th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $3.20.
Shares of Cascadian Therapeutics (NASDAQ:CASC) traded down 2.349% during midday trading on Monday, hitting $1.455. The stock had a trading volume of 724,662 shares. The firm’s 50-day moving average price is $1.32 and its 200-day moving average price is $1.17. Cascadian Therapeutics has a 1-year low of $0.82 and a 1-year high of $3.75. The stock’s market cap is $196.88 million.
Cascadian Therapeutics (NASDAQ:CASC) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by $0.14. During the same quarter in the prior year, the firm posted ($0.11) earnings per share. Analysts forecast that Cascadian Therapeutics will post $5.02 earnings per share for the current year.
In other news, insider Scott Dunseth Myers purchased 45,000 shares of the company’s stock in a transaction on Wednesday, August 17th. The stock was purchased at an average price of $1.15 per share, with a total value of $51,750.00. Following the completion of the purchase, the insider now directly owns 107,500 shares in the company, valued at approximately $123,625. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 19.40% of the company’s stock.
About Cascadian Therapeutics
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
Receive News & Stock Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related stocks with our FREE daily email newsletter.